Insider · CIK 0002009903
Michael Austwick
director
Files at VRNA (Verona Pharma plc). First filing Aug 5, 2025, latest Aug 5, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $148k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Verona Pharma plc | $148k 11,288 shares | -47% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | VRNA Verona Pharma plc | DDisposition to issuer Ordinary Shares | -12,712 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | DDisposition to issuer Share Options (Right to Buy)derivative | -144,000 | - | - | 0 | Oct 8, 2025 |
| Aug 1, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares | +24,000 | $0.00 | $0 | 24,000 | Aug 5, 2025 |
| Aug 1, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares | -11,288 | $13.14 | $148k | 12,712 | Aug 5, 2025 |
| Aug 1, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Stock Unitsderivative | -24,000 | $0.00 | $0 | 72,000 | Aug 5, 2025 |
| Apr 25, 2025 | VRNA Verona Pharma plc | AGrant or award Restricted Share Unitsderivative | +96,000 | $0.00 | $0 | 96,000 | Apr 29, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.